Department of Pharmacy, Uppsala University , SE-751 23 Uppsala, Sweden.
J Med Chem. 2014 Apr 10;57(7):3005-10. doi: 10.1021/jm401963n. Epub 2014 Mar 20.
Optimization of drug efficacy in the brain requires understanding of the local exposure to unbound drug at the site of action. This relies on measurements of the unbound drug fraction (fu,brain), which currently requires access to brain tissue. Here, we present a novel methodology using homogenates of cultured cells for rapid estimation of fu,brain. In our setup, drug binding to human embryonic kidney cell (HEK293) homogenate was measured in a small-scale dialysis apparatus. To increase throughput, we combined drugs into cassettes for simultaneous measurement of multiple compounds. Our method estimated fu,brain with an average error of 1.9-fold. We propose that our simple method can be used as an inexpensive, easily available and high-throughput alternative to brain tissues excised from laboratory animals. Thereby, estimates of unbound drug exposure can now be implemented at a much earlier stage of the drug discovery process, when molecular property changes are easier to make.
优化脑部药物疗效需要了解作用部位未结合药物的局部暴露情况。这依赖于对未结合药物分数(fu,brain)的测量,而这目前需要获取脑组织。在这里,我们提出了一种使用培养细胞匀浆的新方法,可快速估算 fu,brain。在我们的方案中,通过小型透析装置测量了药物与人胚肾细胞(HEK293)匀浆的结合情况。为了提高通量,我们将药物组合成盒,以同时测量多种化合物。我们的方法估算 fu,brain 的平均误差为 1.9 倍。我们提出,我们的简单方法可以作为一种经济实惠、易于获得且高通量的替代方案,替代从实验室动物中切除的脑组织。因此,现在可以在药物发现过程的更早阶段实施未结合药物暴露的估算,此时更容易进行分子特性的改变。